Market open
Praxis Precision Medicines/$PRAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Ticker
$PRAX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
116
ISIN
US74006W2070
Website
PRAX Metrics
BasicAdvanced
$756M
-
-$10.79
2.68
-
Price and volume
Market cap
$756M
Beta
2.68
52-week high
$91.83
52-week low
$26.70
Average daily volume
469K
Financial strength
Current ratio
12.42
Quick ratio
12.274
Long term debt to equity
0.243
Total debt to equity
0.243
Management effectiveness
Return on assets (TTM)
-39.95%
Return on equity (TTM)
-63.56%
Valuation
Price to revenue (TTM)
89.962
Price to book
1.72
Price to tangible book (TTM)
1.72
Price to free cash flow (TTM)
-4.458
Growth
Revenue change (TTM)
270.02%
Earnings per share change (TTM)
-20.93%
3-year earnings per share growth (CAGR)
-46.56%
What the Analysts think about PRAX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Praxis Precision Medicines stock.
PRAX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PRAX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PRAX News
AllArticlesVideos
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
GlobeNewsWire·2 weeks ago
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Praxis Precision Medicines stock?
Praxis Precision Medicines (PRAX) has a market cap of $756M as of May 15, 2025.
What is the P/E ratio for Praxis Precision Medicines stock?
The price to earnings (P/E) ratio for Praxis Precision Medicines (PRAX) stock is 0 as of May 15, 2025.
Does Praxis Precision Medicines stock pay dividends?
No, Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Praxis Precision Medicines dividend payment date?
Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Praxis Precision Medicines?
Praxis Precision Medicines (PRAX) has a beta rating of 2.68. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.